TICS: Transcranial Magnetic Stimulation for Intervening in Children With Tourette's Syndrome (CIHR)

Tic Disorders Clinical Trial

— TICS-CIHR  

Official title:

TICS: Transcranial Magnetic Stimulation for Intervening in Children With Tourette's Syndrome

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03844919
• Other study ID #: REB18-0220
• Status: Recruiting
• Phase: N/A
• Start date: September 1, 2019
• Est. completion date: November 1, 2022

Study information

• Verified date: November 2021
• Source: University of Calgary
• Contact: Frank MacMaster, PhD
• Phone: 4039552784
• Email: fmacmast[@]ucalgary.ca
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Tourette's Syndrome (TS) is characterized by repetitive movements and vocalizations called tics. Due to the suffering caused by TS, children and adolescents often require treatment for their tics. The investigators' research focuses on developing novel repetitive transcranial magnetic stimulation (rTMS) interventions for child and adolescent neuropsychiatric disorders. In this project, the investigators will determine the effect of pairing 3 weeks of rTMS and HRT on tic severity and plasticity as indexed by supplementary motor area (SMA) y-aminobutyric acid (GABA) concentration and functional connectivity of the SMA to the primary motor cortex (M1) in children and adolescents with TS. Children (N = 50, 6-18 years) with TS will be randomized to either a (1) rTMS+HRT arm, or (2) sham rTMS+HRT. Outcome measures will examine tic severity (primary), brain chemistry and function (secondary) at baseline and then at week 7. The investigators' proposed aims are: (Aim 1) To determine the effect of paired rTMS and HRT on tic severity as measured by the Yale Global Tic Severity Scale (YGTSS) by comparing it to sham rTMS + HRT. 1-1: The investigators hypothesize that tic severity will decrease from baseline to post-treatment. 1-2: The investigators also hypothesize that the reduction in tic severity will be greater in the paired treatment group (rTMS+HRT > Sham rTMS+HRT). (Aim 2) To determine the effect of paired rTMS and HRT on brain plasticity compared to sham rTMS + HRT. 2-1: The investigators hypothesize that patients treated with the paired rTMS and HRT will have a greater increase in GABA concentration comparted to sham and HRT. 2-2: The investigators also hypothesize that functional connectivity between the SMA and M1 will be greater with paired treatment (rTMS+HRT > Sham rTMS+HRT).

Description:

Tourette's Syndrome (TS) is characterized by repetitive movements and vocalizations called tics. Due to the suffering caused by TS, children and adolescents often require treatment for their tics. Tic severity predicts poor outcomes across physical, psychological, and cognitive domains in youth. Current treatments for TS remain limited in scope and efficacy. Atypical antipsychotics are often used and for many patients have an unacceptable side effect burden. Behavioral treatments, like habit reversal therapy (HRT), show promise and are safe, but are predicated on a certain level of brain maturation to execute. The investigators' research focuses on developing novel repetitive transcranial magnetic stimulation (rTMS) interventions for child and adolescent neuropsychiatric disorders. Plasticity, precision, and pairing are key considerations in this process. In this project, the investigators will determine the effect of pairing 3 weeks of rTMS and HRT on tic severity and plasticity as indexed by supplementary motor area (SMA) y-aminobutyric acid (GABA) concentration and functional connectivity of the SMA to the primary motor cortex (M1) in children and adolescents with TS. The investigators will use functional magnetic resonance imaging (fMRI) and robot controlled rTMS to precisely target the SMA. The investigators believe this pairing will provide improved relief by inducing plasticity to retrain the brain to be better at suppressing tics at an earlier age than usually expected. Children (N = 50, 6-18 years) with TS will be randomized to either a (1) rTMS+HRT arm, or (2) sham rTMS+HRT. Outcome measures will examine tic severity (primary), brain chemistry and function (secondary) at baseline and then at week 7. The investigators' proposed aims are: (Aim 1) To determine the effect of paired rTMS and HRT on tic severity as measured by the Yale Global Tic Severity Scale (YGTSS) by comparing it to sham rTMS + HRT. 1-1: The investigators hypothesize that tic severity will decrease from baseline to post-treatment. 1-2: The investigators also hypothesize that the reduction in tic severity will be greater in the paired treatment group (rTMS+HRT > Sham rTMS+HRT). (Aim 2) To determine the effect of paired rTMS and HRT on brain plasticity compared to sham rTMS + HRT. 2-1: The investigators hypothesize that patients treated with the paired rTMS and HRT will have a greater increase in GABA concentration comparted to sham and HRT. 2-2: The investigators also hypothesize that functional connectivity between the SMA and M1 will be greater with paired treatment (rTMS+HRT > Sham rTMS+HRT).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 50
• Est. completion date: November 1, 2022
• Est. primary completion date: May 1, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 6 Years to 18 Years

Eligibility

Inclusion Criteria:

1. Diagnosis of Tourette's syndrome

2. IQ greater than 80

3. English fluency (to enable assent and consent).

Exclusion Criteria:

1. Diagnosis of mania or schizophrenia

2. Impediments to TMS or MRI.

Related Conditions & MeSH terms

• Tic Disorders
• Tourette Syndrome

Intervention

Device:
• rTMS + CBIT
Repetitive Transcranial Magnetic Stimulation (rTMS) parameters are: intensity 100% resting motor threshold (RMT), frequency 1Hz, duration = 30 minutes (1800 stimulations; 900 per side), target - the supplementary motor area (SMA). Treatments occur on weekdays (T - F) for four weeks (20 total). The Comprehensive Behavioral Intervention for Tics (CBIT) will be completed over eight sessions that will average 60 minutes in duration. First, participants will undergo awareness training. Participants will then be introduced to competing response training, which involves performing a voluntary behaviour designed to disrupt the execution of the tic. The eight sessions will occur on Mondays, once a week for six weeks and then on weeks 8 and 10.

Behavioral:
• Sham rTMS + CBIT
Sham rTMS (sham coil) will be paired with CBIT. Sham rTMS will be delivered over the same time-frame as above. CBIT will be identical to the above.

Locations

Country	Name	City	State
Canada	Alberta Children's Hospital	Calgary	Alberta

Sponsors (2)

Lead Sponsor	Collaborator
University of Calgary	Canadian Institutes of Health Research (CIHR)

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Yale Global Tic Severity Scale Total Tic score (YGTSS) post CBIT	30% reduction in YGTSS (~9 point reduction); 30% reduction in Yale Global Tic Severity Scale Total Tic score (YGTSS) (~9 point reduction).; A higher score on all scales suggests a more severe tics.; The YGTSS provides two tic severity scores: Total Motor (0 to 25); Total Phonic (0 to 25); These are summed to form the Total Tic Severity Score (0 to 50). This is the measure for this outcome variable.; There is also the separate Impairment Dimension Score (0 to 50).; The total score is hence 0 to 100 (sum of Total Tic Severity Score and Impairment Dimension Score).	Baseline to week 11
Primary	Yale Global Tic Severity Scale Total Tic score (YGTSS)	30% reduction in Yale Global Tic Severity Scale Total Tic score (YGTSS) (~9 point reduction).; A higher score on all scales suggests a more severe tics.; The YGTSS provides two tic severity scores: Total Motor (0 to 25); Total Phonic (0 to 25); These are summed to form the Total Tic Severity Score (0 to 50). This is the measure for the primary outcome variable.; There is also the separate Impairment Dimension Score (0 to 50).; The total score is hence 0 to 100 (sum of Total Tic Severity Score and Impairment Dimension Score).	Baseline to week 7
Secondary	Supplementary Motor Area (SMA) GABA concentration as measured by LCModel (Institutional Units)	10% increase in GABA concentration in the Supplementary Motor Area (SMA) as measured by LCModel (Institutional Units)	Baseline to week 7
Secondary	Functional connectivity of the Supplementary Motor Area (SMA) and the dominant Primary Motor Cortex (M1)	Functional connectivity, as measured using SPM12, of the Supplementary Motor Area (SMA) and the dominant Primary Motor Cortex (M1).	Baseline to week 7